普通烟草CESA基因家族成员的鉴定、亚细胞定位及表达分析

纤维素合成酶蛋白(cellulose-synthase proteins, CESA)是一类质膜定位蛋白,以蛋白复合体的形式存在于质膜上合成纤维素,在细胞壁建成和植物生长发育过程中起着非常重要的作用。本研究利用CESA蛋白保守域序列PF03552检索普通烟草(Nicotiana tabacum L.)蛋白序列,并通过拟南芥(Arabidopsis thaliana)10个CESA蛋白序列在普通烟草基因组数据库中利用TBLASTN程序进行比对,共获得21条NtCESA基因候选序列,对这些序列进行蛋白序列理化性质分析、系统进化树构建、基因结构分析、保守结构域及跨膜区分析和组织表达模式分析,并对NtCESA9和NtCESA14两个蛋白进行了亚细胞定位实验。结果表明：获得的21条NtCESA蛋白序列的理化性质相似;系统进化分析将21个NtCESA基因和10个AtCESA基因分成5个分支,每一个分支各成员之间的进化相对保守,基因结构类似,不同分支之间的基因结构差异也较小;NtCESA蛋白结构域相对保守,都含有CESA蛋白典型的N端锌指结构、C端跨膜区和DDD-QXXRW保守功能域;组织表达分析结果表明,大部分NtCESA基因在幼苗和成熟期烟草的根、叶、胚芽和愈伤组织中都有表达,同一个分支中的基因表达模式基本一致,并且NtCESA基因参与初/次生细胞壁纤维素的合成与该基因编码蛋白的跨膜区数目存在关联,表明NtCESA基因家族成员功能上的复杂性;亚细胞定位结果证实NtCESA9和NtCESA14为质膜定位蛋白。本研究为烟草CESA基因家族功能的深入研究奠定了基础。     

粗山羊草CCT基因家族进化及节律表达分析

CCT家族基因广泛参与植物花期的调控过程,粗山羊草(Aegilops tauschii Coss.)作为小麦D基因组供体,给小麦带来新的花期及适应性相关基因。研究粗山羊草CCT家族基因不仅可为小麦进化、驯化和演变规律提供参考,还有助于认识粗山羊草作为杂草的生态适应性。粗山羊草基因组中26个CCT基因进化分析后发现Group A、Group C、GroupH和Group G中的13个Aet CCT成员出现了快速进化;Group A中有42.1%的位点存在正选择效应,表明快速进化提高了粗山羊草的适应性。基因结构分析表明CCT结构域在Aet CCT家族中保守性很高,但不同基因内含子和外显子的排布差异较大,特异Motif可能是不同亚家族基因间功能差异的重要原因。Aet CCT4、Aet CCT7、Aet CCT8、Aet CCT11、Aet CCT12、Aet CCT16、Aet CCT17、Aet CCT19、Aet CCT21和Aet CCT22的表达具有明显的"生物钟效应",呈现出24 h的节律性表达,且基本都处于快速进化的Group A、Group C、GroupH和Group I。研究结果表明,这些成员可能参与花期调控等生长发育过程,在粗山羊草的适应性形成过程中发挥了作用。     

斑马鱼转座子时空表达特性

转座子是基因组中可移动和扩展的元件,能够插入新的位点,影响基因组和基因的结构和功能,是基因组进化的内在驱动。为探讨转座子的时空表达特性,首先通过生物信息学方法鉴定出斑马鱼9个疑似活性转座子,包括DNA转座子Tc1家族(Tc-a、Tc-b、Tc-c、Tc-d、Tc-e)、反转录转座子ERV家族(ERV-1、ERV-2)和LINE家族(L1-323、L1-21),然后采用实时荧光定量PCR法检测上述转座子在斑马鱼早期胚胎发育7个阶段及成鱼各主要脏器的表达活性。结果表明:Tc1家族在0.75、2.00、3.00 h各阶段无转录活性,在6.00、15.00、24.00、48.00 h各阶段各转座子均有较高转录活性;反转录转座子转录活性最早出现于3 h,最晚出现于15 h,且随着发育时间的延长,转录活性显著增强。9种转座子在成鱼心脏、大脑、肌肉、肝脏、睾丸和卵巢均有表达,且大脑和心脏中的表达水平显著高于其他组织,睾丸表达水平最低。分析表明转座子的表达具有时间和组织的特异性,可能参与斑马鱼胚胎和组织器官发育调控,尤其是大脑和心脏发育。这些结果为进一步研究转座子是否具有基因表达调控功能提供重要参考。     

Tyrosinase inhibitory activity of three new glycosides from Breynia fruticosa

Two new flavanone glycoside derivatives and one new sulfur-containing spiroacetal glycoside, (2R, 3R)-3-acetyl-7-methoxy-(−)-epicatechin 5-O-(6-isobutanoyl)-β-d-glucopyranoside (1), (2R, 3R)-3-acetyl-7-methoxy-(−)-epicatechin 5-O-[6-(2-methylbutanoyl)]-β-d-glucopyranoside (2) and 4-[(carboxymethyl)thio]-5′-hydroxy-phyllaemblic acid O-β-d-glucopyranosyl-(1 → 2)-β-d-glucopyranoside ester (3), along with twelve known flavonoids and one known sulfur-containing spiroacetal glycoside, were isolated from Breynia fruticosa. Their structures were elucidated by the use of extensive spectroscopic methods (UV, IR, HR-ESI-MS, 1D and 2D NMR, and CD). The in vitro inhibition of tyrosinase activity by all of these compounds was also evaluated, and we concluded that the flavanol-containing 5-O- and 7-O-sugar moieties possessed more potent effects than the other compounds examined herein.     

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies

Deficiency of interleukin (IL)-36 receptor antagonist (DITRA) syndrome is a rare autosomal recessive disease caused by mutations in IL36RN. IL-36R is a cell surface receptor and a member of the IL1R family that is involved in inflammatory responses triggered in skin and other epithelial tissues. Accumulating evidence suggests that IL-36R signaling may play a role in the pathogenesis of psoriasis. Therapeutic intervention of IL-36R signaling offers an innovative treatment paradigm for targeting epithelial cell-mediated inflammatory diseases such as the life-threatening psoriasis variant called generalized pustular psoriasis (GPP). We report the discovery and characterization of MAB92, a potent, high affinity anti-human IL-36 receptor antagonistic antibody that blocks human IL-36 ligand (α, β and γ)-mediated signaling. In vitro treatment with MAB92 directly inhibits human IL-36R-mediated signaling and inflammatory cytokine production in primary human keratinocytes and dermal fibroblasts. MAB92 shows exquisite species specificity toward human IL-36R and does not cross react to murine IL-36R. To enable in vivo pharmacology studies, we developed a mouse cross-reactive antibody, MAB04, which exhibits overlapping binding and pharmacological activity as MAB92. Epitope mapping indicates that MAB92 and MAB04 bind primarily to domain-2 of the human and mouse IL-36R proteins, respectively. Treatment with MAB04 abrogates imiquimod and IL-36-mediated skin inflammation in the mouse, further supporting an important role for IL-36R signaling in epithelial cell-mediated inflammation.     

马尾松半同胞子代苗期与幼林生长变异分析及家系选择

为探讨马尾松改良种子园半同胞家系子代的生长变异情况,测定分析了26个家系1 年生苗高、地径和0.5年生、1.5 年生及2.5 年生幼林的树高、地径、胸径、材积和冠幅等生长指标。结果表明,各性状在家系间均存在极显著差异,参试群体的树高、胸径、材积和冠幅的家系遗传力大于0.8,且前三个性状的单株遗传力大于0.4,说明上述性状是遗传力较高的性状。2.5年生材积生长量显著高于普通生产种的优良家系有19个,入选率为73%,树高、胸径和材积的遗传增益分别为2.76%、3.60%和8.49%,与初级种子园混合种和普通生产种相比,其材积分别提高55.28%和218.28%。     

Mitochondria-mediated apoptosis in mammals

The mitochondria-mediated caspase activation pathway is a major apoptotic pathway characterized by mitochondrial outer membrane permeabilization (MOMP) and subsequent release of cytochrome c into the cytoplasm to activate caspases. MOMP is regulated by the Bcl-2 family of proteins. This pathway plays important roles not only in normal development, maintenance of tissue homeostasis and the regulation of immune system, but also in human diseases such as immune disorders, neurodegeneration and cancer. In the past decades the molecular basis of this pathway and the regulatory mechanism have been comprehensively studied, yet a great deal of new evidence indicates that cytochrome c release from mitochondria does not always lead to irreversible cell death, and that caspase activation can also have non-death functions. Thus, many unsolved questions and new challenges are still remaining. Furthermore, the dysfunction of this pathway involved in cancer development is obvious, and targeting the pathway as a therapeutic strategy has been extensively explored, but the efficacy of the targeted therapies is still under development. In this review we will discuss the mitochondria-mediated apoptosis pathway and its physiological roles and therapeutic implications.     

基于ChIP-Seq进行肿瘤睾丸抗原XAGE-1b基因表达蛋白的DNA结合位点鉴定

XAGE-1b（X antigen family member 1B）属于XAGE亚家族,是一种肿瘤 睾丸抗原（cancer/testis antigen,CTA）,表达于正常人睾丸组织和多种类型的肿瘤细胞中.本实验室前期研究发现,该基因在涎腺腺样囊性癌高转移细胞系中呈高表达.为了进一步研究XAGE-1b下游调控基因,本实验采用ChIP Seq技术筛查XAGE 1b蛋白质可能存在的DNA结合片段. 结果发现,XAGE-1b下游调控基因富集于细胞分裂（cell division,P-Value＝7.95e-04）、细胞周期调控（cell cycle,P-Value＝5.532e-03）、及癌症相关基因（GESA/MSigDB module_11,P-Value＝2.010e-06）中．同时发现,XAGE-1b下游调控多个基因的表达产物（NCBI/interactions 22827,P-Value＝4.678e-06）能与原癌基因c-Myc的启动子抑制蛋白PUF60发生蛋白质相互作用,并通过qPCR进行了验证．这些研究对阐明XAGE-1b在肿瘤细胞的增殖和转移中的作用有重要意义.